Target intelligence / Profile preview

Neisseria meningitidis serogroup C capsular oligosaccharide (MenC OS)

Target
MenC OS
Molecular classification
Other
01

Overview

The capsular oligosaccharide of Neisseria meningitidis serogroup C is a key bacterial surface antigen composed of alpha(2->9)-linked sialic acid residues. It acts as a critical virulence factor by forming a protective capsule that shields the pathogen from host complement-mediated killing and opsonophagocytosis, allowing the bacteria to survive in the bloodstream and cause invasive disease. This oligosaccharide is a primary target for immunotherapies and vaccines designed to prevent meningococcal meningitis and septicemia. In modern conjugate vaccines, these oligosaccharide epitopes are chemically linked to carrier proteins like CRM197 or tetanus toxoid to recruit T-cell help, converting a T-cell independent response into a robust, T-cell dependent immune response. This conjugation is essential for inducing high-affinity IgG antibodies and establishing long-term immunological memory, particularly in infants and young children. The resulting antibodies specifically recognize the capsular epitopes, facilitating bacterial clearance via complement activation and phagocytosis.

Other names
Neisseria meningitidis serogroup C capsular polysaccharideMeningococcal group C capsular polysaccharideMeningococcal group C capsular oligosaccharideMenC capsular polysaccharideMenC capsular oligosaccharideGroup C meningococcal polysaccharideNmC polysaccharideNmC capsular polysaccharidealpha(2->9)-linked sialic acid polymer
02

Mechanism of action

Vaccines containing this antigen induce the production of protective bactericidal antibodies (IgG) that promote complement-mediated lysis and opsonophagocytosis of Neisseria meningitidis serogroup C bacteria.

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Capsule switchingVariable immunogenicityO-acetylation variabilityHyporesponsiveness after repeated doses of plain polysaccharide vaccines
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Serum bactericidal antibody (SBA) titersAnti-capsular IgG antibody levelsCapsular polysaccharide levels in cerebrospinal fluidCapsular polysaccharide levels in blood

Beyond the preview

Go deeper on Neisseria meningitidis serogroup C capsular oligosaccharide (MenC OS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis serogroup C capsular oligosaccharide (MenC OS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call